Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum

Key facts

Sponsor

InflaRx GmbH

Principal Investigator

Alex GO Loayza, Prof, MD

university

Intervention

vilobelimab(drug)

Enrollment

54 enrolled

Eligibility

18 years · All sexes

Timeline

2023 – 2025

Study locations (30)

• Aby´s New Generation Research, Inc, Hialeah, Florida, United States
• Dermatology/University of Miami Hospital, Miami, Florida, United States
• University of Central Florida College of Medicine, Orlando, Florida, United States
• ForCare Clinical Research, Tampa, Florida, United States
• Advanced Medical Research, PC, Sandy Springs, Georgia, United States
• Brigham and Women´s Hospital, Boston, Massachusetts, United States
• University of North Carolina at Chapel Hill Department of Dermatology, Chapel Hill, North Carolina, United States
• Ohio State University Wexner Medical Cente OSU Dermatology West, Columbus, Ohio, United States
• Apex Clinical Research Center, Mayfield Heights, Ohio, United States
• Oregon Health and Science University, Portland, Oregon, United States
• University of Pennsylvania, Philadelphia, Pennsylvania, United States
• The University of Texas Health Science Center at Houston, Bellaire, Texas, United States
• Premier Specialists, Kogarah, NewSouth Wales, Australia
• The Alfred Hospital, Melbourne, Melbourne, Victoria, Australia
• Veracity Clinical Research Pty Ltd as trustee for the MLS Trust, Brisbane, Australia
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →